Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer

Gulley, JL; Borre, M; Vogelzang, NJ; Ng, S; Agarwal, N; Parker, CC; Pook, DW; Rathenborg, P; Flaig, TW; Carles, J; Saad, F; Shore, ND; Chen, L; Heery, CR; Gerritsen, WR; Priou, F; Langkilde, NC; Novikov, A; Kantoff, PW

Gulley, JL (reprint author), NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.

JOURNAL OF CLINICAL ONCOLOGY, 2019; 37 (13): 1051

Abstract

PURPOSE PROSTVAC, a viral vector-based immunotherapy, prolonged median overall survival (OS) by 8.5 months versus placebo in metastatic castration-res......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索